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A B S T R A C T   
We document two cases of viremic and prolonged active infection with the severe acute respiratory syndrome 
coronavirus 2 (SARS-CoV-2) where the viral genome was conserved for two months, but infection was with little 
or no symptoms. The first infection persisted for 80 days and the second for 62 days. Clearance of infection 
occurred 40 and 41 days, respectively, after development of detectable antibodies. Both cases were identified 
incidentally in an investigation of reinfection in a cohort of 133,266 laboratory-confirmed infected persons.   
Characterized by high infectiousness (He et al., 2020a; MIDAS On-
line COVID-19 Portal, 2020), the severe acute respiratory syndrome 
coronavirus 2 (SARS-CoV-2) has led to disruptive epidemics globally (De 
Walque et al., 2020; COVID-19 Outbreak Live Update, 2020). The 
epidemic in Qatar, a peninsula in the Arabian Gulf region, was pervasive 
with broad exposure to the infection and >60,000 laboratory-confirmed 
infections per million population (Abu-Raddad et al., 2020a; Al Kuwari 
et al., 2020; Jeremijenko et al., 2020). 
Marked by a centralized and standardized data-capture system of all 
SARS-CoV-2 data and a well-resourced Coronavirus Disease 2019 
(COVID-19) healthcare, Qatar provides an opportunity for conducting 
epidemiological investigations at a national level that are difficult to do 
elsewhere. Recently, we completed an assessment of the risk of rein-
fection and confirmation of reinfection with viral genome sequencing in 
a cohort of 133,266 SARS-CoV-2 laboratory-confirmed infected persons 
(Abu-Raddad et al., 2020b). The study incidentally identified two cases 
of prolonged active infection with conserved virus for about two months 
(Abu-Raddad et al., 2020b). 
In-depth retrospective case investigation was completed for these 
two cases. We retrieved their SARS-CoV-2 testing and hospitalization 
records from the centralized and standardized national database main-
tained at Hamad Medical Corporation (HMC), the nationally-designated 
provider for all COVID-19-related healthcare needs. The study was 
approved by HMC and Weill Cornell Medicine-Qatar Institutional 
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Review Boards. 
Viral genome sequencing was conducted using an amplicon-based 
strategy. Viral genome differences were detected using standard single 
nucleotide polymorphism (SNP) calling in order to collect information 
on allele balances and ensure that quasi-species sites were well docu-
mented. Nucleotide differences between strains were determined using a 
collection of samples from the cohort of SARS-CoV-2 laboratory- 
confirmed infected persons as a reference (Abu-Raddad et al., 2020b). 
Differences between the viral strains collected from the same patient at 
different time points (deviations over the course of infection) was the 
main goal in this study rather than to investigate evolutionary changes 
across the population of patients. Each of the two cases reported here 
had only two polymerase chain reaction (PCR) positive samples; no 
sequential samples were available for further analysis. To ensure that 
time-course viral samples indeed derived from the same patient, we 
sequenced residual DNA in the samples from both time-points (prior to 
DNAse treatment) using Accel-Amplicon® Panel for 15 genes of the 
human genome (Swift Biosciences, Ann Arbor, MI, USA; Cat. No. CP- 
CQ6110-1008) as per the manufacturers’ recommended protocol. The 
residual human DNA in each swab serves as an internal control system to 
identify the patient from whom the swab was collected. Sequencing of 
the 15 genes and documentation of variable sites (SNPs) in the ampli-
cons showed that there was high correlation between the human DNA 
sequences of the first and second swabs for the patients tested. Given 
that only 17 SNPs were compared, this cannot completely exclude swabs 
originating from other patients, however, the chances given these in-
ternal control results are not likely. 
Fig. 1 summarizes the investigation’s key results. Case 1 was a 
Kenyan man in the 40–44 years age group, with a history of controlled 
hypertension, who first underwent PCR testing for SARS-CoV-2 on June 
3, 2020 based on clinical suspicion of infection, but no record was found 
of specific symptoms. His test result was positive with an average cycle 
threshold (Ct) value of 22.7 across the different target proteins using the 
Roche cobas® SARS-CoV-2 Test (Roche, Switzerland). Per guidelines, 
the person was in isolation for two weeks, but was not retested during 
this period. Serological testing performed 40 days later (on July 13, 
2020) using the Roche Elecsys® Anti-SARS-CoV-2 (Roche, Switzerland) 
yielded an anti-SARS-CoV-2 positive result, but with a low optical 
density of 4.8 (result interpretation per manufacturer’s instructions: 
reactive at optical density cut-off index ≥1.0 and non-reactive at cutoff 
index <1.0) (The Roche Group, 2020). 
This person was PCR re-tested for SARS-CoV-2 infection on August 7, 
2020 (65 days after the first positive swab) as part of a workplace survey 
testing. Although asymptomatic at this time, he was found PCR positive 
with an average Ct value of 22.6 using the TaqPath™ COVID-19 Combo 
Kit (Thermo Fisher Scientific, USA) on a ABI 7500 FAST (Thermo Fisher, 
USA). Of note that the choice of platform for PCR testing (Roche cobas® 
SARS-CoV-2 Test versus TaqPath™ COVID-19 Combo Kit) depended on 
instrument availability within the laboratory—test results for this 
analysis were retrieved retrospectively. Viral genome sequencing of the 
Fig. 1. History of SARS-CoV-2 infection in the two prolonged active-infection cases with high viral RNA concentration and conserved viral genome.  
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first and subsequent positive swabs indicated infection with the same 
virus with no evidence for reinfection (Fig. 2). A third PCR test per-
formed two weeks later (on August 22, 2020) was conducted as part of a 
random testing survey, but he was PCR negative. No specific COVID-19 
treatment was administered and no hospitalization occurred at any time 
indicating the infection was of mild severity. No other clinical or 
contact-tracing data relevant to explain the prolonged infection or its 
infection transmission implications were available. 
Case 2 was a Qatari woman in the 40–44 years age group who was on 
treatment for hypertension using bisprolol and more recently amlodi-
pine/perindropil (post-infection), hypothyroidism using levothyroxine, 
and pre-diabetes using metformin. She was first identified as PCR pos-
itive on June 12, 2020 during contact tracing, with an average Ct value 
of 23.7 across the different target proteins, assessed using the TaqPath™ 
COVID-19 Combo Kit (Thermo Fisher Scientific, USA) on a ABI 7500 
FAST (Thermo Fisher, USA). She was asymptomatic. Per guidelines, the 
person was in isolation for two weeks, but was not retested during this 
period. Serological testing performed 21 days later (on July 03, 2020) 
using the Roche Elecsys® Anti-SARS-CoV-2 (Roche, Switzerland) iden-
tified detectable antibodies with a low optical density of 2.4. 
A subsequent PCR test performed on August 8, 2020 (57 days after 
the first positive swab) at port of entry (upon returning from travel 
abroad) yielded a positive result, with absence of symptoms, but with an 
average Ct value of 20.5 using the Thermo Fisher platform. Viral genome 
sequencing of the first and subsequent positive swabs indicated infection 
with the same virus with no evidence for reinfection (Fig. 2). The woman 
was re-tested few days later (on August 13, 2020) for clinical suspicion 
with symptoms suggestive of an upper respiratory tract infection, but 
was found PCR negative. No further case investigation (PCR testing or 
clinical follow-up) was performed. Two subsequent serological tests 
performed on August 20 and August 23 yielded anti-SARS-CoV-2 posi-
tive results with high optical densities of 121.0 and 126.0, respectively. 
No specific COVID-19 treatment was administered and no hospitaliza-
tion occurred at any time indicating that infection was of mild severity. 
No other clinical or contact-tracing data relevant to explain the pro-
longed infection or its infection transmission implications were 
available. 
Based on current understanding of the natural history and infec-
tiousness profile of SARS-CoV-2 infection, individuals typically develop 
latent infection for about 4 days (Lauer et al., 2020; Li et al., 2020b; 
Rothe et al., 2020; Zou et al., 2020), and then transition into an infec-
tious period of about four days (He et al., 2020b; Li et al., 2020b; Rothe 
et al., 2020; Zou et al., 2020). A fraction of individuals develop symp-
toms typically about two days after transitioning into the infectious 
period, the time around which SARS-CoV-2 viral RNA concentration 
starts declining (Centers for Disease Control and Prevention, 2020; He 
et al., 2020b). The infectious period is sometimes followed by a pro-
longed PCR positivity period at high Ct value (>30) that may extend for 
several weeks, but such PCR positivity reflects very low level of viral 
replication, or more often non-viable remnants of the virus (Sethuraman 
et al., 2020; Wajnberg et al., 2020). 
However, our cases had evidence for viremic prolonged PCR posi-
tivity with a conserved virus at high enough viral concentration that was 
conducive for quality genome sequencing (Fig. 2). Clearance of infection 
occurred 40 and 41 days, respectively, after first evidence of detectable 
antibodies (Fig. 1). With the low optical density in the first serological 
test, but very high optical density weeks later (Fig. 1), development of 
detectable antibodies appears to have been a slow process, particularly 
for case 2 for whom there were records for three serological tests. Our 
findings concur with observations from other studies documenting 
viremic and prolonged PCR positivity in similarly immunocompetent 
patients (Hong et al., 2020; Li et al., 2020a). 
In conclusion, we documented two cases of viremic and prolonged 
active SARS-CoV-2 infection with a conserved viral genome for over two 
months, but with little or no symptoms. Although this is of concern given 
implications on current guidelines for isolation and discharge from 
isolation (World Health Organization, 2020), these occurrences are 
likely rare, as they were identified incidentally in an investigation of 
reinfection in a cohort of 133,266 SARS-CoV-2 laboratory-confirmed 
infected persons (Abu-Raddad et al., 2020b). Onward infection trans-
mission and other public health consequences of such cases remain 
unknown. 
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Fig. 2. Viral genome sequencing analysis of the paired viral specimens of the first and last positive swabs for the two active-infection cases with high viral RNA 
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